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Abstract
Effective, sensitive, and reliable diagnostic reagents are of paramount importance for combating the
ongoing coronavirus disease 2019 (COVID-19) pandemic at the time there is no preventive vaccine nor
specific drug available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It would be
an absolute tragedy if currently used diagnostic reagents are undermined in any manner. Based on the
genotyping of 7818 SARS-CoV-2 genome samples collected up to May 1, 2020, we reveal that essentially
all of the current COVID-19 diagnostic targets have had mutations. We further show that SARS-CoV-2 has
the most devastating mutations on the targets of various nucleocapsid (N) gene primers and probes, which
have been unfortunately used by countries around the world to diagnose COVID-19. Our findings explain
what has seriously gone wrong with a specific diagnostic reagent made in China. To understand whether
SARS-CoV-2 genes have mutated unevenly, we have computed the mutation ratio and mutation h-index
of all SARS-CoV genes, indicating that the N gene is the most non-conservative gene in the SARS-CoV-2
genome. Our findings enable researchers to target the most conservative SARS-CoV-2 genes and proteins
for the design and development of COVID-19 diagnostic reagents, preventive vaccines, and therapeutic
medicines.
The coronavirus disease 2019 (COVID-19) pandemic outbreak caused by severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2), first reported in Wuhan in December 2019, has spread to 187 countries
and territories with more than 3.481million infection cases and 244,633 fatalities worldwide byMay 1, 2020.
Additionally, travel restrictions, quarantines, and social distancing measures have essentially put the global
economy on hold. Unfortunately, there is no specific medication nor vaccine for COVID-19 at this moment.
Therefore, reopening economies depends vitally on effective COVID-19 diagnostic testing, patient isola-
tion, contact tracing, and quarantine. It cannot be overemphasized the importance of diagnostic testing for
combating COVID-19.
We reveal that there are many mutations on the COVID-19 diagnostic targets commonly used around
the world, including those designated by the United States (US) Centers for Disease Control and Prevention
(CDC). Thesemutations seriously undermine the current global effort in COVID-19 testing, prevention, and
control. Approved by the US Food and Drug Administration (FDA), the CDC has detailed guidelines for
COVID-19 diagnostic testing, called “CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diag-
nostic Panel” ( https://www.fda.gov/media/134922/download). The CDC has designated two oligonu-
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cleotide primers from regions of the virus nucleocapsid (N) gene, i.e., N1 and N2, as probes for the specific
detection of SARS-CoV-2. The panel has also selected an additional primer/probe set, the human RNase
P gene (RP), as control samples. Many other diagnostic primers and probes based on RNA-dependent
RNA polymerase (RdRP, also named IP2, IP4, ORF1ab, or ORF1b), envelope (E), and N genes have been
designed [3] and/or designated by the World Health Organization (WHO) as shown in Table S1 of the
Supporting Material, which provides the details of 41 commonly used diagnostic primers and probes [10].
Diagnostic test reagents were designed based on early clinical specimens containing a full spectrum
of SARS-CoV-2, particularly the reference genome collected on January 5, 2020, in Wuhan (SARS-CoV,
NC004718) [12]. It has been reported that different primers and probes show nonuniform performance
[1, 2, 4, 6, 7, 11].
Our findings are based on the genotyping of 7818 SARS-CoV-2 genome samples collected up to May
1, 2020, which have 5117 single mutations over about 29.8 kilobases (kb). These mutations occur on all of
SARS-CoV-2 genes and proteins, indicating alarming impacts on the current efforts in the development of
COVID-19 diagnostic tests, prevention vaccines, and therapeutic medicines. We employK-meansmethods
to cluster these mutations, resulting in globally at least five distinct subtypes of SARS-CoV-2 genomes, from
early Cluster I to late Cluster V. Table 1 shows cluster distributions of samples (NNS) and total mutation
counts (NTF) for 11 countries.
Table 1: The cluster distributions of samples (NNS) and total mutation counts (NTF) for 11 countries.
Cluster I Cluster II Cluster III Cluster IV Cluster V
Country NNS NTF NNS NTF NNS NTF NNS NTF NNS NTF
US 739 5149 248 1623 514 4968 60 555 677 5035
CA 40 240 13 72 28 193 14 119 19 126
AU 63 434 354 3810 182 1315 99 873 96 691
UA 2 13 554 3785 607 4206 597 5730 60 457
CN 23 54 179 865 7 63 1 13 1 7
DE 0 0 12 42 3 18 8 70 20 131
FR 0 0 14 55 105 755 6 49 66 463
UK 0 0 23 90 10 55 4 30 0 0
IT 0 0 6 134 22 161 12 140 0 0
JP 0 0 67 194 0 0 0 0 0 0
KR 0 0 26 160 0 0 0 0 0 0
The US, Canada (CA), Australia (AU), Ukraine (UA), and China (CN) samples involve all of the five
clusters. Among them, China initially had samples only in Clusters I and II and its sample distributions
reached to other Clusters after March 2020. Germany (DE) and France (FR) samples are in Cluster II, III,
IV, and V. United Kingdom (UK) and Italy (IT) samples are mainly in Clusters II, III, and IV. Japan (JP) and
Korea (KR) samples belong to Cluster II only. Cluster II is common to all countries.
Table 2 provides all mutations on various primers and probes and their occurring frequencies in various
clusters. More detailed mutation information is given in Tables S2-S42 of the Supporting Material. It is
interesting to note that N-China-F [10] is the most inefficient reagent among all primers/probes and its
SARS-CoV-2 target has eight mutations involving samples in all five clusters, which may explain many
media reports about the inefficiency of certain COVID-19 diagnostic kits made in China. Note that primers
and probes typically have a small length of around 20 nucleotides.
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Table 2: Summary of mutations on COVID-19 diagnostic primers and probes and their occurrence frequencies in clusters.
Primer/probe # of mutations Total frequency Cluster I Cluster II Cluster III Cluster IV Cluster V
RX7038-N1 primer (Fw)a 4 5 0 1 3 1 0
RX7038-N1 primer (Rv)a 6 42 0 28 3 13 0
RX7038-N2 primer (Fw)a 2 5 0 1 2 1 1
RX7038-N2 primer (Rv)a 3 9 2 5 2 0 0
RX7038-N3 primer (Fw) [6] 5 110 0 98 9 2 1
RX7038-N3 primer (Rv) [6] 6 17 1 3 11 1 1
N1-U.S.-P [10] 3 116 1 108 5 2 0
N2-U.S.-P [10] 3 31 27 3 2 1 0
N3-U.S.-P [10] 8 19 4 5 6 2 2
N-Sarbeco-Fb [3] 5 15 3 4 6 0 2
N-Sarbeco-Pb [3] 2 3 0 0 1 2 0
N-Sarbeco-Rb [3] 7 33 7 6 8 0 12
N-China-F [10] 8 4194 9 76 29 4062 15
N-China-R [10] 7 14 2 1 7 3 1
N-China-P [10] 0 0 0 0 0 0 0
N-HK-F [10] 4 44 0 3 16 25 0
N-HK-R [10] 3 12 2 0 7 2 1
N-JP-F [10] 2 5 3 2 0 0 0
N-JP-R [10] 2 4 0 2 2 0 0
N-TL-F [10] 7 40 1 32 4 3 0
N-TL-R [10] 6 14 0 6 6 1 1
N-TL-P [10] 3 12 0 1 2 9 0
E-Sarbeco-F1c 1 1 0 1 0 0 1
E-Sarbeco-R2c 2 2 1 1 0 0 0
E-Sarbeco-P1c 2 8 0 6 2 0 0
E-DE-F [10] 1 2 0 0 2 0 0
nCoV-IP2-12669Fwc 0 0 0 0 0 0 0
nCoV-IP2-12759Rvc 7 39 1 13 22 0 3
nCoV-IP2-12696bProbe(+)c 1 4 0 0 4 0 0
nCoV-IP4-14059Fwc 1 8 0 0 8 0 0
nCoV-IP4-14146Rv c 3 13 0 4 5 0 4
nCoV-IP4-14084Probe(+)c 3 9 0 4 5 0 0
RdRP-SARSr-F2d 3 13 0 0 11 0 2
RdRP-SARSr-R1 [3]d 1 1 0 0 1 0 0
RdRP-SARSr-P2 [3]d 2 6 0 5 1 0 0
ORF1ab-China-F [10] 0 0 0 0 0 0 0
ORF1ab-China-R [10] 0 0 0 0 0 0 0
ORF1ab-China-P [10] 0 0 0 0 0 0 0
ORF1b-nsp14-HK-F [10] 2 2 0 0 1 0 1
ORF1b-nsp14-HK-R [10] 4 9 0 6 2 2 0
ORF1b-nsp14-HK-P [10] 2 4 1 0 2 1 0
a https://www.fda.gov/media/136691/download
b https://www.eurosurveillance.org/content/table/10.2807/1560-7917.ES.2020.25.3.2000045.t1?fmt=ahah&fullscreen=true
c https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6 2
d https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c 2
Currently, all the primers and probes used in the US target the N gene [10]. Unfortunately, Table 2 shows
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that all of the US CDC designated COVID-19 diagnostic primers have been compromised. The targets of
N gene primers and probes used in Japan, Thailand, and China, including Hong Kong, except for that of
N-China-P, have undergone multiple mutations involving many clusters as well.
It is interesting to note that the targets of four E gene primers and probes have only six mutations.
No mutation has been found on the targets of RNA-dependent RNA polymerase-based primers or probes,
nCoV-IP2-12669Fw primer, ORF1ab-China-F, ORF1ab-China-R, and ORF1ab-China-P. However, the target
of nCoV-IP2-12759R recommended by Institut Pasteur, Paris has 7 mutations. Overall, targets of the enve-
lope and RNA-dependent RNA polymerase based primers and probes have fewer mutations than those of
the N gene. This observation leads us to wonder whether the N gene is particularly prone to mutations.
Table 3: Gene-specific statistics of SARS-CoV-2 single mutations.
Gene type Gene site Gene length Unique SNPs mutation ratio h-index
NSP1 266:805 540 121 0.2241 8
NSP2 806:2719 1914 407 0.2126 16
NSP3 2720:8554 5835 912 0.1563 18
NSP4 8555:10054 1500 203 0.1353 11
NSP5(3CL) 10055:10972 918 130 0.1416 10
NSP6 10973:11842 870 133 0.1529 8
NSP7 11843:12091 249 37 0.1486 5
NSP8 12092:12685 594 77 0.1296 4
NSP9 12686:13024 339 48 0.1416 6
NSP10 13025:13441 417 44 0.1055 4
NSP11 13442:13480 39 5 0.1282 2
RNA-dependent-polymerase 13442:16236 2796 363 0.1298 15
Helicase 16237:18039 1803 227 0.1259 12
3’-to-5’ exonuclease 18040:19620 1581 241 0.1524 10
endoRNAse 19621:20658 1038 143 0.1378 10
2’-O-ribose methyltransferase 20659:21552 894 115 0.1286 8
Spike protein 21563:25384 3819 622 0.1629 17
ORF3a protein 25393:26220 825 231 0.28 13
Envelope protein 26245:26472 225 30 0.1333 6
Membrane glycoprotein 26523:27191 666 105 0.1577 11
ORF6 protein 27202:27387 183 47 0.2568 6
ORF7a protein 27394:27759 363 88 0.2424 6
ORF7b protein 27756:27887 129 10 0.0775 2
ORF8 protein 27894:28259 363 90 0.2479 8
Nucleocapsid protein 28274:29533 1257 340 0.2705 29
ORF10 protein 29558:29674 114 27 0.2368 4
To understand whether there is a differentiation in SARS-CoV-2 gene mutation pattern, we analyze the
gene-specific statistics of SARS-CoV-2 single mutations. Table 3 lists the mutation ratio, i.e., number of
unique single-nucleotide polymorphisms (SNPs) over the corresponding gene length, for all SARS-CoV-2
genes. A smaller mutation ratio for a given gene indicates its higher degree of conservativeness. Clearly,
ORF7b gene has the smallest mutation ratio of 0.0775. The N gene has the second largest mutation ratio
of 0.2705, which is very close to the largest ratio of 0.2800 for ORF3a gene. To take into the consideration
of mutation frequency, we introduce the mutation h-index, defined as the maximum value of h such that
the given gene section has h single mutations that have each occurred at least h times. Normally, larger
genes tend to have higher h-index. Table 3 shows that, with a moderate length, the N gene has the largest
h-index of 29, which is significantly higher the second largest h-index of 18 for NSP3. Therefore, it was truly
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unfortunate for the world to have selected SARS-CoV-2 N gene primers and probes as diagnostic reagents
for combating COVID-19.
In summary, the targets of currently used COVID-19 diagnostic reagents have had numerous mutations
that have seriously undermined our ability to combat COVID-19. In the Supporting Material, we provide
a full list of all 5117 SNP variants, including their positions and mutation types. This information, together
with ranking of the degree of the conservativeness of SARS-CoV-2 genes or proteins given in Table 3, en-
ables researchers to avoid non-conservative genes (or their proteins) and mutated nucleotide segments in
designing COVID-19 diagnosis, vaccine and drugs.
Methods and materials SARS-CoV-2 genome sequences from infected individuals dated between Jan-
uary 5, 2020, and May 1, 2020, are downloaded from the GISAID database [8] ( https://www.gisaid.org/).
We only consider the records in GISAID with complete genomes and submission dates. The resulting 7818
complete genome sequences are rearranged according to the reference SARS-CoV-2 genome [12] by using
the Clustal Omega multiple sequence alignment with default parameters [9]. Gene variants are recorded as
single-nucleotide polymorphisms (SNPs). The Jaccard distance [5] is employed to compute the similarities
among genome samples. The resulting distance matrix is used in the k-means clustering of all samples.
1 Data Availability
The nucleotide sequences of the SARS-CoV-2 genomes used in this analysis are available, upon free regis-
tration, from the GISAID database ( https://www.gisaid.org/). Supporting Material presents a list of 5117
SNP variants of 7818 SARS-CoV-2 samples across the world, a list of 41 commonly used diagnostic primers
and probes, and tables of mutation details on 41 diagnostic primers and probes. The acknowledgments of
the SARS-COV-2 genomes are also given in the Supporting Material.
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